Orchard Therapeutics Closes $110 Million Series B for Gene Therapy – Equities.com
Equities.com |
Orchard Therapeutics Closes $110 Million Series B for Gene Therapy
Equities.com Orchard's lead product, OTL-101, is an autologous ex-vivo lentiviral gene therapy in development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID), a rare and life-threatening inherited disorder of the immune system … |
